Vantage logo

Persistence pays off for Kala

The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.

Vantage logo

Safety scare knocks Novartis

Heightened Beovu safety concerns could turn into a big problem for Novartis, while rival Regeneron will make the most of any uncertainty.